Kliniken & Institute ... Institute Pathologisches Institut... Abteilungen Neuropathologie Forschung Publikationen 2011 ...

Publikationen 2011

Differential retinoic acid signaling in tumors of long- and short-term glioblastoma survivors. Barbus S, Tews B, Karra D, Hahn M, Radlwimmer B, Delhomme N, Hartmann C, Felsberg J, Krex D, Schackert G, Martinez R, Reifenberger G, Lichter P.
Journal of the National Cancer Institute. 2011 103(7): 598-606

Mutational analysis of D2HGDH and L2HGDH in brain tumors without IDH1 or IDH2 mutations. Brehmer S, Pusch S, Schmieder K, von Deimling A, Hartmann C.
Neuropathol Appl Neurobiol. 2011 37(3): 330-332

Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation specific monoclonal antibody. Capper D, Preusser M, Habel A, Sahm F, Ackermann U, Schindler G, Pusch S, Mechtersheimer G, Zentgraf H, von Deimling A.
Acta Neuropathol. 2011 122(1): 11-19

Mutation specific IDH1 antibody differentiates oligodendrogliomas and oligoastrocytomas from other brain tumors with oligodendroglioma-like morphology. Capper D, Reuss D, Schittenhelm J, Hartmann C, Bremer J, Sahm F, Harter P, Jeibmann A, von Deimling A.
Acta Neuropathol. 2011 121(2): 241-252

Oncogenic FAM131B-BRAF fusion resulting from 7q34 deletion comprises an alternative  mechanism of MAPK pathway activation in pilocytic astrocytoma. Cin H, Meyer C, Herr R, Janzarik W, Lambert S, Jones D, KJacob K, A. B, Witt H, Remke M, Bender S, Falkenstein F, Anh T, Olbrich H, von Deimling A, Pekrun A, Kulozik A, Gnekow A, Scheuerlen W, Witt O, Omran H, Jabado N, Collins P, Brummer T, Marschalek R, Lichter P, Korshunov A, Pfister S.
Acta Neuropathol. 2011 121(6): 763-774

Prognostic significance of IDH-1 and MGMT in patients with glioblastoma: One step forward, and one step back? Combs S, Rieken S, Wick W, Abdollahi A, von Deimling A, Debus J, Hartmann C.
Radiation Oncology. 2011 6: 115

Improved correlation of neuropathological classification according to the adapted WHO classification and outcome after radiation therapy in patients with atypical and anaplastic meningiomas. Combs S, Schulz-Ertner D, Debus J, von Deimling A, Hartmann C.
Int J Radiat Oncol Biol Phys. 2011 81(5): 1415-1421

Prognostic stratification of gliomatosis cerebri by IDH1 R132H and INA expression Desestret A, Ciccarino P, Ducray F, Crinière E, Boisselier B, Labussiere M, Polivka M, Idbaih A, Kaloshi G, von Deimling A, Hoang-Xuan K, Delattre J, Mokhtari K, Sanson M.
J. Neurooncol. 2011 105(2): 219-224

An unusual case of optic neuritis. Doegel D, Mueller W, Deckert M, Lenhard T, Schmidt-Bacher A, Storch-Hagenlocher B, Biller A, Wildemann B.
J Neurol Sci. 2011 304(1-2): 138-141

Functional characterization of a BRAF insertion mutant associated with pilocytic astrocytoma. Eisenhardt AE, Olbrich H, Roring M, Janzarik W, Van Anh TN, Cin H, Remke M, Witt H, Korshunov A, Pfister SM, Omran H, Brummer T.
Int J Cancer. 2011 129(9): 2297-2303

PROX1 is a predictor of survival for gliomas WHO grade II. Elsir T, Qu M, Berntsson S, Orrego A, Olofsson T, Lindström M, Nistér M, von Deimling A, Hartmann C, Ribom D, Smits A.
Br J Cancer. 2011 104(11): 1747-1754

Identification of diagnostic serum protein profiles of glioblastoma patients. Elstner A, Stockhammer F, Nguyen-Dobinsky T-N, Nguyen Q, Pilgermann I, Gill A, Guhr A, Zhang T, von Eckardstein K, Picht T, Veelken J, Martuza R, von Deimling A, Kurtz A.
J Neurooncol. 2011 102(1): 71-80

Absence of chromosome 19q13.41 amplification in a case of atypical teratoid/rhabdoid tumor with ependymoblastic differentiation. Gessi M, Pfister S, Hans VH, Korshunov A, Pietsch T.
Acta Neuropathol. 2011 121(2): 283-285

Temozolomide and 13-cis retinoic acid in patients with anaplastic gliomas: a prospective single-arm monocentric phase-II study (RNOP-05). Grauer O, Pascher C, Hartmann C, Zeman F, Weller M, Proescholdt M, Brawanski A, Pietsch T, Wick W, Bogdahn U, Hau P.
J Neurooncol. 2011 104(3): 801-809

An activated mutant BRAF kinase domain is sufficient to induce pilocytic astrocytoma in mice. Gronych J, Korshunov A, Bageritz J, Milde T, Jugold M, Hambardzumyan D, Remke M, Hartmann C, Witt H, Jones DT, Witt O, Heiland S, Bendszus M, Holland EC, Pfister S, Lichter P.
J Clin Invest. 2011 121(4): 1344-1348

Molecular markers in low-grade gliomas: predictive or prognostic? Hartmann C, Hentschel B, Tatagiba M, Schramm J, Schnell O, Seidel C, Stein R, Reifenberger G, Pietsch T, von Deimling A, Loeffler M, Weller W.
Clin Cancer Res. 2011 17(13): 4588-4599

Genetic aberrations leading to MAPK pathway activation mediate oncogene-induced senescence in sporadic pilocytic astrocytomas. Jacob K, Quang-Khuong DA, Jones DT, Witt H, Lambert S, Albrecht S, Witt O, Vezina C, Shirinian M, Faury D, Garami M, Hauser P, Klekner A, Bognar L, Farmer JP, Montes JL, Atkinson J, Hawkins C, Korshunov A, Collins VP, Pfister SM, Tabori U, Jabado N.
Clin Cancer Res. 2011 17(14): 4650-4660

The Nature and Timing of Specific Copy Number Changes in the Course of Molecular Progression in Diffuse Gliomas: Further Elucidation of Their Genetic "Life Story". Jeuken JW, Sijben A, Bleeker FE, Boots-Sprenger SH, Rijntjes J, Gijtenbeek JM, Mueller W, Wesseling P.
Brain Pathol. 2011 21(3): 308-320

Diagnostic markers for glioblastoma. Jung CS, Unterberg AW, Hartmann C.
Histol Histopathol. 2011 26(10): 1327-1341

Preoperative shock wave treatment enhances ischemic tissue survival, blood flow and angiogenesis in a rat skin flap model. Keil H, Mueller W, Herold-Mende C, Gebhard MM, Germann G, Engel H, Reichenberger MA. Int J Surg. 2011 9(4): 292-296

Secondary anaplastic astrocytoma developing in a young adult with autoimmune lymphoproliferative syndrome (ALPS). Kita D, Hayashi Y, Watanabe T, Korshunov A, von Deimling A, Nakada M, Kasahara Y, Zen Y, Hamada J, Hayashi Y.
Neuropathol Appl Neurobiol. 2011 37(4): 423-427

The transcription factor evi-1 is overexpressed, promotes proliferation, and is prognostically unfavorable in infratentorial ependymomas. Koos B, Bender S, Witt H, Mertsch S, Felsberg J, Beschorner R, Korshunov A, Riesmeier B, Pfister S, Paulus W, Hasselblatt M.
Clin Cancer Res. 2011 17(11): 3631-3637

Hot spots in 18FET-PET delineate malignant tumor parts within suspected WHO grade II glioma. Kunz M, Thon N, Eigenbrod S, Hartmann C, Egensperger R, Herms J, Geisler J, la Fougere C, Lutz J, Linn J, Kreth S, von Deimling A, Tonn J, Kretzschmar H, Poepperl G, Kreth F.
Neuro-Oncology. 2011 13(3): 307-316

Effector T-cell infiltration positively impacts survival of glioblastoma patients and is impaired by tumor-derived TGF-β. Lohr J, Ratliff T, Huppertz A, Ge Y, Dictus C, Ahmadi R, Grau S, Hiraoka N, Eckstein V, Ecker R, Korff T, von Deimling A, Unterberg A, Beckhove P, Herold-Mende C.
Clin Cancer Res. 2011 17(13): 4296-4308

A novel human high-risk ependymoma stem cell model reveals the differentiation-inducing potential of the histone deacetylase inhibitor Vorinostat. Milde T, Kleber S, Korshunov A, Witt H, Hielscher T, Koch P, Kopp H-G, Jugold M, Deubzer H, Oehme I, Lodrini M, H-J. G, Benner A, Brüstle O, Gilbertson R, von Deimling A, Kulozik A, Pfister S, Martin-Villalba A, Witt O.
Acta Neuropathol. 2011 122(5): 637-650

Genome-wide molecular characterization of central nervous system primitive neuroectodermal tumor and pineoblastoma. Miller S, Rogers HA, Lyon P, Rand V, Adamowicz-Brice M, Clifford SC, Hayden JT, Dyer S, Pfister S, Korshunov A, Brundler MA, Lowe J, Coyle B, Grundy RG.
Neuro-Oncology. 2011 13(8): 866-879

Genetische und epigenetische Veränderungen in glialen Hirntumoren. Mueller W.
In: Forum Moderne Pathologie. ed P. Schirmacher. Shaker, Aachen 2011:
Accurate classification of metastatic brain tumors using a novel microRNA-based test. Mueller WC, Spector Y, Edmonston TB, St Cyr B, Jaeger D, Lass U, Aharonov R, Rosenwald S, Chajut A.
Oncologist. 2011 16(2): 165-174

The potential of relaxation-weighted sodium magnetic resonance imaging as demonstrated on brain tumors. Nagel AM, Bock M, Hartmann C, Gerigk L, Neumann JO, Weber MA, Bendszus M, Radbruch A, Wick W, Schlemmer HP, Semmler W, Biller A.
Investigative Radiology. 2011 46(9): 539-547

Pediatric and adult sonic hedgehog medulloblastomas are clinically and molecularly distinct. Northcott PA, Hielscher T, Dubuc A, Mack S, Shih D, Remke M, Al-Halabi H, Albrecht S, Jabado N, Eberhart CG, Grajkowska W, Weiss WA, Clifford SC, Bouffet E, Rutka JT, Korshunov A, Pfister S, Taylor MD.
Acta Neuropathol. 2011 122(2): 231-240

Medulloblastoma Comprises Four Distinct Molecular Variants. Northcott PA, Korshunov A, Witt H, Hielscher T, Eberhart CG, Mack S, Bouffet E, Clifford SC, Hawkins CE, French P, Rutka JT, Pfister S, Taylor MD.
J Clin Oncol. 2011 29(11): 1408-1414

An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor. Opitz C, Litzenburger U, Sahm F, Ott M, Tritschler I, Trump S, Schumacher T, Jestaedt L, Schrenk D, Weller M, Jugold M, Guillemin G, Miller C, Lutz C, Radlwimmer B, Lehman I, von Deimling A, Wick W, Platten M.
Nature. 2011 478(7368): 197-203

The indoleamine-2,3-dioxygenase (IDO) inhibitor 1-methyl-D-tryptophan upregulates IDO1 in human cancer cells. Opitz CA, Litzenburger UM, Opitz U, Sahm F, Ochs K, Lutz C, Wick W, Platten M.
PLoS One. 2011 6(5): e19823

Prognostic but not predictive role of platelet-derived growth factor receptors in patients with recurrent glioblastoma. Paulsson J, Lindh M, Jarvius M, Puputti M, Nister M, Nupponen N, Paulus W, Söderberg O, Dresemann G, von Deimling A, Joensuu H, Östman A, Hasselblatt M. International Journal of Cancer. 2011 128(8): 1981-1988

IDH testing in diagnostic neuropathology: review and practical guideline article invited by the Euro-CNS research committee. Preusser M, Capper D, Hartmann C. Clinical neuropathology. 2011 30(5): 217-230

Bimolecular-fluorescence complementation assay to monitor kinase-substrate interactions in vivo. Pusch S, Dissmeyer N, Schnittger A.
Methods Mol Biol. 2011 779: 245-257

Glioma IDH1 mutation patterns off the beaten track. Pusch S, Sahm F, Meyer J, Mittelbronn M, Hartmann C, von Deimling A. Neuropathol Appl Neurobiol. 2011 37(4): 428-430

Comparison of extracorporal shock wave pretreatment to classic surgical delay in a random pattern skin flap model. Reichenberger MA, Keil H, Mueller W, Herold-Mende C, Gebhard MM, Germann G, Engel H.
Plast Reconstr Surg. 2011 127(5): 1830-1837

Optimal timing of extracorporeal shock wave treatment to protect ischemic tissue. Reichenberger MA, Keil H, Mueller W, Herold-Mende C, Meirer R, Gebhard MM, Germann G, Engel H.
Ann Plast Surg. 2011 67(5): 539-544

FSTL5 is a marker of poor prognosis in Non-WNT/Non-SHH medulloblastoma. Remke M, Hielscher T, Korshunov A, Northcott P, Bender S, Kool M, Westermann F, Benner A, Cin H, Ryzhova M, Sturm D, Witt H, Haag D, Toedt G, Wittmann A, Schöttler A, von Bueren A, von Deimling A, Rutkowski S, Scheurlen W, Kulozik A, Taylor M, Lichter P, Pfister S.
J Clin Oncol. 2011 29(29): 3852-3861

Adult Medulloblastoma is Comprised of Three Major Molecular Variants. Remke M, Hielscher T, Northcott P, Witt H, Ryzhova M, Wittmann A, Benner A, von Deimling A, Scheurlen W, Perry A, Croul S, Kulozik A, Lichter P, Taylor M, Pfister S, Korshunov A.
J Clin Oncol. 2011 29(19): 2717-2723

Immunohistochemical analysis of 1844 human epithelial and hematopoietic tumors and sarcomas for IDH1R132H mutation. Sahm F, Capper D, Meyer J, Hartmann C, Herpel E, Andrulis M, Mechterheimer G, Petersen I, Paulus W, von Deimling A.
Histopathology. 2011 58(7): 1167-1172

Analysis of BRAF V600E mutation in 1320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma and ganglioglioma. Schindler G, Capper D, Meyer J, Janzarik W, Omran H, Herold-Mende C, Schmieder K, Wesseling P, Mawrin C, Hasselblatt M, Louis D, Korshunov A, Pfister S, Hartmann C, Paulus W, Reifenberger G, von Deimling A.
Acta Neuropathol. 2011 121(3): 397-405

Confirmation of R132H mutation of isocitrate dehydrogenase 1 as an independent prognostic factor in anaplastic astrocytoma. Schittenhelm J, Mittelbronn M, Meyermann R, Melms A, Tatagiba M, Capper D.
Acta Neuropathol. 2011 122(5): 651-652

The efficacy of bipolar and multipolar radiofrequency ablation of lung neoplasms - results of an ablate and resect study. Schneider T, Reuss D, Warth A, Schnabel PA, von Deimling A, Herth FJ, Dienemann H, Hoffmann H.
Eur J Cardiothorac Surg. 2011 39(6): 968-973

The p53 tumor suppressor is stabilized by Inhibitor of Growth 1 (ING1) by blocking polyubiquitination. Thalappilly S, Feng X, Pastyryeva S, Suzuki K, Muruve D, Larocque D, Richard S, Truss M, von Deimling A, Riabowol K, Tallen G.
PLoS One. 2011 6(6): e21065

Molecular Signatures Classify Astrocytic Gliomas by IDH1 Mutation Status. Toedt G, Barbus S, Wolter M, Felsberg J, Tews B, Blond F, Sabel M, Hofmann M, Becker N, Hartmann C, Ohgaki H, von Deimling A, Wiestler O, Hahn M, Lichter P, Reifenberger G, Radlwimmer B.
International Journal of Cancer. 2011 128(5): 1095-1103

The Next Generation of Glioma Biomarkers: MGMT Methylation, BRAF Fusions, and IDH1 Mutations. von Deimling A, Korshunov A, Hartmann C.
Brain Pathol. 2011 21(1): 74-87

Isocitrate dehydrogenase mutations: a challenge to traditional views on the genesis and malignant progression of gliomas. Weller M, Wick W, von Deimling A.
Glia. 2011 59(8): 1200-1204

R132H-mutation of isocitrate dehydrogenase-1 is not sufficient for HIF-1 alpha upregulation in adult glioma. Williams S, Karajannis M, Chiriboga L, von Deimling A, Zagzag D.
Acta Neuropathol. 2011 121(2): 279-281

Delineation of two clinically and molecularly distinct subgroups of posterior fossa ependymoma. Witt H, Mack S, Ryzhova M, Bender S, Sill M, Isserlin R, Benner A, Hielscher T, Milde T, Remke M, Jones D, Northcott P, Garcia L, Bertrand K, Wittmann A, Yao Y, Roberts S, Massimi L, van Meter T, Weiss W, Gupta N, Grajkowska W, Lach B, Cho J, von Deimling A, Kulozik A, Witt O, Bader G, Hawkins C, Guha A, Rutka J, Lichter P, Korshunov A, Taylor M, Pfister S.
Cancer Cell. 2011 20(2): 143-157

FISH-based detection of 1p 19q codeletion in oligodendroglial tumors: procedures and protocols for neuropathological practice - a publication under the auspices of the Research Committee of the European Confederation of Neuropathological Societies (Euro-CNS). Woehrer A, Sander P, Haberler C, Kern S, Maier H, Preusser M, Hartmann C, Kros JM, Hainfellner JA.
Clinical neuropathology. 2011 30(2): 47-55

Embryonal tumor with abundant neuropil and true rosettes (ETANTR) with loss of morphological but retained genetic key features during progression. Woehrer A, Slavc I, Peyrl A, Czech T, Dorfer C, Prayer D, Stary S, Streubel B, Ryzhova M, Korshunov A, Pfister SM, Haberler C.
Acta Neuropathol. 2011 122(6): 787-790

Hemangiopericytomas grade II are not benign tumors. Zweckberger K, Jung CS, Mueller W, Unterberg AW, Schick U. Acta Neurochir (Wien). 2011 153(2): 385-394